Ubs Group Ag Tiziana Life Sciences LTD Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TLSA
# of Institutions
25Shares Held
908KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA220KShares$199,7640.0% of portfolio
-
Hsbc Holdings PLC London, X0125KShares$114,0820.0% of portfolio
-
Morgan Stanley New York, NY111KShares$100,5690.0% of portfolio
-
Zhang Financial LLC69.4KShares$63,1420.0% of portfolio
-
Ausdal Financial Partners, Inc. Davenport, IA55.7KShares$50,6870.01% of portfolio
About Tiziana Life Sciences Ltd
- Ticker TLSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,273,000
- Market Cap $93.1M
- Description
- Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...